Sep 20, 2021

PolyPid to Present at Upcoming Cantor Fitzgerald Global Healthcare Conference

PETAH TIKVA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced its participation in the Cantor
Sep 13, 2021

PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer

Positive Results in Two Animal Models of Glioblastoma Multiform (GBM) demonstrated that Single Local Treatment of OncoPLEX Significantly Inhibited Tumor Growth and Prolonged Survival Company Expects a Pre-IND Meeting with the U.S. FDA by Year End and Potential Initiation of Phase 1/2 Clinical Trial
Aug 17, 2021

PolyPid to Present at First World Association Against Infection in Orthopaedics and Trauma Congress

Virtual Presentation to be led by PolyPid Co-Founder and CSO on August 28, 2021 PETACH TIKVA, Israel, Aug. 17, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ), a late-stage biopharma focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical
Aug 11, 2021

PolyPid Ltd. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

•  Recruitment Progressing as Planned with Over   3 00 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100  in Abdominal Surgery •  FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX 100   for the Prevention of Surgical Site Infections in
Aug 09, 2021

PolyPid to Present at the Investor Summit Virtual Conference on August 18, 2021

PETACH TIKVA, Israel, Aug. 09, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that Executive Vice President and Chief Financial Officer
Jul 28, 2021

PolyPid to Report Second Quarter 2021 Financial Results and Operational Highlights on August 11, 2021

PETAH TIKVA, Israel, July 28, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will report its second quarter 2021 financial
Jul 12, 2021

PolyPid Strengthens Executive Team, Appointing Dr. Anthony Senagore as Senior Medical Director

PETAH TIKVA, Israel, July 12, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ), a late-stage biopharma company focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical outcomes, today announced that it has appointed leading colorectal surgeon
Jun 23, 2021

PolyPid Presents today at The Raymond James Human Health Innovation Conference

Presentation led by PolyPid EVP & CFO is taking place today on June 23, 2021 at 9:20am EDT PETAH TIKVA, Israel, June 23, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled,
Jun 02, 2021

PolyPid to Present at Upcoming Healthcare Investor Conferences

PETAH TIKVA, Israel , June 02, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that members of its executive management team will
May 19, 2021

PolyPid Announces Positive FDA Type B Meeting Feedback for D-PLEX₁₀₀ Development Program

FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX 100   for the Prevention of Surgical Site Infections in Colorectal Surgery. Enrollment in  Phase 3 SHIELD I Trial of D-PLEX 100  in Abdominal Surgery Continues to Advance ; Over 200 Patients Enrolled to
Displaying 1 - 10 of 16

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >
D-PLEX100

D-PLEX100

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >
D-PLEX1000

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >